The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings (Q33870816)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings |
scientific article |
Statements
1 reference
The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings (English)
1 reference
Magnhild Sandberg-Wollheim
1 reference
Gabrielle Kornmann
1 reference
Dorina Bischof
1 reference
Margaretha Stam Moraga
1 reference
Brian Hennessy
1 reference
Enrica Alteri
1 reference
1 April 2011
1 reference
1 reference
17
1 reference
431-440
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference